Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 13624
Country/Region: Côte d'Ivoire
Year: 2016
Main Partner: Sante Espoir Vie - Cote d'Ivoire
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $5,230,178 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $496,085
Care: Orphans and Vulnerable Children (HKID) $416,028
Care: TB/HIV (HVTB) $309,685
Care: Pediatric Care and Support (PDCS) $154,423
Laboratory Infrastructure (HLAB) $32,000
Testing: HIV Testing and Counseling (HVCT) $299,206
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $543,621
Treatment: Adult Treatment (HTXS) $2,382,907
Treatment: Pediatric Treatment (PDTX) $596,223
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: 10-14 Female 2017 3
GEND_GBV Age/Sex: 15-19 Female 2017 6
GEND_GBV Age/Sex: 20-24 Female 2017 10
GEND_GBV Age/Sex: 25-49 Female 2017 116
GEND_GBV Age/Sex: 50+ Female 2017 1
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 29
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 106
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 31
GEND_GBV Number of people receiving post-GBV care 2017 137
GEND_GBV Sum of Age/Sex Disaggregates 2017 3
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 9,469
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 10,217
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 93,204
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 100,680
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 213,570
HTS_TST Service Delivery Point (Community): Index testing 2017 568
HTS_TST Service Delivery Point (Community): Other 2017 1,709
HTS_TST Service Delivery Point (Facility): Inpatient 2017 100,859
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 2,022
HTS_TST Service Delivery Point (Facility): Outpatient 2017 11,858
HTS_TST Service Delivery Point (Facility): PMTCT 2017 94,000
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 2,554
HTS_TST Sum of Aggregated Age/Sex <15 2017 19,686
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 193,884
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 213,570
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 473
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 554
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 3,802
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 4,105
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 21
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 26
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 26
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 2
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 19
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 1
OVC_SERV Age/Sex: 18+ Female 2017 1,577
OVC_SERV Age/Sex: 18+ Male 2017 832
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 2,385
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 2,436
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 7,230
OVC_SERV Sum of Age/Sex disaggregates 2017 2,409
PMTCT_ART Already on ART at beginning of current pregnancy 2017 921
PMTCT_ART New on ART 2017 1,081
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 95,191
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,159
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 578
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 34
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 22
PMTCT_EID Sum of Infant Age disaggregates 2017 1,737
PMTCT_STAT By: Known positives at entry 2017 921
PMTCT_STAT By: Number of new positives identified 2017 1,170
PMTCT_STAT Number of new ANC and L&D clients 2017 100,135
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 95,191
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,091
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 16
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 302
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 7
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 222
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 575
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 547
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 2,741
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 301
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 2,096
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 344
TB_SCREENDX Screen Result: Screened Positive for TB 2017 2,741
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 18,767
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 7,329
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 683
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 696
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 27,475
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 40
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 994
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 73
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,447
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 2,554
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 2,718
TX_CURR Age/Sex: <1 2017 263
TX_CURR Age/Sex: <1-9 2017 1,434
TX_CURR Age/Sex: 10-14 Female 2017 313
TX_CURR Age/Sex: 10-14 Male 2017 347
TX_CURR Age/Sex: 15-19 Female 2017 280
TX_CURR Age/Sex: 15-19 Male 2017 99
TX_CURR Age/Sex: 20-24 Female 2017 1,191
TX_CURR Age/Sex: 20-24 Male 2017 232
TX_CURR Age/Sex: 25-49 Female 2017 15,276
TX_CURR Age/Sex: 25-49 Male 2017 7,093
TX_CURR Age/Sex: 50+ Female 2017 1,983
TX_CURR Age/Sex: 50+ Male 2017 2,033
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,158
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,199
TX_CURR Aggregated Age/Sex: 15+ Female 2017 18,730
TX_CURR Aggregated Age/Sex: 15+ Male 2017 9,457
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 30,544
TX_CURR Sum of age/sex disaggregates 2017 379
TX_CURR Sum of Aggregated Age/Sex <15 2017 2,357
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 28,187
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 30,544
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 759
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 790
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 7,424
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 3,934
TX_NEW By Age/Sex: <1 2017 169
TX_NEW By Age/Sex: 1-9 2017 943
TX_NEW By Age/Sex: 10-14 Female 2017 205
TX_NEW By Age/Sex: 10-14 Male 2017 232
TX_NEW By Age/Sex: 15-19 Female 2017 98
TX_NEW By Age/Sex: 15-19 Male 2017 98
TX_NEW By Age/Sex: 20-24 Female 2017 444
TX_NEW By Age/Sex: 20-24 Male 2017 98
TX_NEW By Age/Sex: 25-49 Female 2017 6,109
TX_NEW By Age/Sex: 25-49 Male 2017 2,871
TX_NEW By Age/Sex: 50+ Female 2017 773
TX_NEW By Age/Sex: 50+ Male 2017 867
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 12,907
TX_NEW Sum of Age/Sex disaggregates 2017 11,795
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 12,907
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 32,057
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 24,034
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 868
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 885
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 14,803
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 7,478
TX_PVLS Numerator: Indication: Routine 2017 24,034
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,164
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,202
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 19,753
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 9,938
TX_PVLS_den Denominator: Indication: Routine 2017 32,057
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 15
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 108
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 21
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 25
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 48
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 14
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 226
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 38
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,883
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,347
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 395
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 437
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 84
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 85
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,552
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,836
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 5,557
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 6,949
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 20
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 149
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 27
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 28
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 62
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 19
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 282
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 53
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,618
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,679
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 487
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 525
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 112
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 112
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,449
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,276
Cross Cutting Budget Categories and Known Amounts Total: $4,827,018
Human Resources for Health $4,080,555
Food and Nutrition: Policy, Tools, and Service Delivery $313,889
Food and Nutrition: Commodities $156,944
Water $52,315
Renovation $171,000
Gender: Gender Based Violence (GBV) $52,315
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation